Revvity Faces Investors: AI, Growth, and Margins Under Scrutiny

By Sarah Hughes

WALTHAM, MA – February 17, 2026 – Life sciences giant Revvity, Inc. (NYSE: RVTY) is preparing for a critical series of investor presentations in early March, where its top executives will face a market balancing recent financial beats against a cautious outlook for the year ahead. President and CEO Prahlad Singh and CFO Max Krakowiak are slated to hold fireside chats at the Raymond James, TD Cowen, and Barclays healthcare conferences, providing a platform to detail the company’s strategic priorities.

The presentations come just weeks after Revvity reported fourth-quarter 2025 earnings that surpassed analyst expectations. However, the company's stock saw a pre-market dip following the announcement, signaling investor apprehension over its modest growth guidance for 2026. Stakeholders will be listening intently for a more compelling narrative that bridges the gap between the company’s ambitious innovation agenda and its near-term financial projections.

A Look Back at a "Dynamic" 2025

Revvity closed 2025 on a high note, posting fourth-quarter revenues of $772 million, a 6% year-over-year increase that beat analyst forecasts. Adjusted earnings per share (EPS) for the quarter came in at $1.70, a significant 20% jump from the prior year and well ahead of consensus estimates. For the full year, the company delivered total revenue of approximately $2.9 billion and an adjusted EPS of $5.06, outperforming its initial guidance.

Beneath the surface of these strong headline numbers lies a more complex story. The company's performance was largely driven by its Diagnostics segment, which saw robust 7% organic growth fueled by strong demand for immunodiagnostics and reproductive health testing. In contrast, the Life Sciences segment reported flat organic growth, reflecting what the company described as subdued spending in academic and government markets.

Furthermore, while revenue and earnings exceeded expectations, adjusted operating margins for the full year declined to 27.1% from 28.3% in 2024. This margin pressure, particularly a 230 basis point decline in the otherwise booming Diagnostics segment in Q4, is a key point of concern that investors will expect management to address. The company successfully navigated what CEO Prahlad Singh called a “dynamic year,” but the focus now shifts to whether it can translate that resilience into profitable expansion.

The 2026 Outlook and Investor Questions

Looking ahead, Revvity has projected organic revenue growth of just 2-3% for 2026, with total revenues forecast between $2.96 billion and $2.99 billion. While the company guided for adjusted EPS growth of 6-8% to a range of $5.35 to $5.45, underpinned by an expected improvement in operating margins to 28.0%, the conservative top-line forecast has tempered market enthusiasm.

This cautious guidance has left Wall Street with a mixed sentiment. Analyst ratings currently hover between “Hold” and “Moderate Buy,” with average 12-month price targets ranging from approximately $113 to $120. This suggests that while analysts see potential upside, they are waiting for more definitive catalysts. Recent actions, such as a downgrade from Bank of America to “neutral” in December, contrast with firms like TD Cowen and Barclays raising their price targets, reflecting the divided opinion.

The central question for Singh and Krakowiak at the upcoming conferences will be how Revvity plans to re-accelerate growth and deliver on its promised margin recovery. Investors will be seeking clarity on the headwinds in the Life Sciences sector and the specific operational efficiency initiatives that management believes will drive margin expansion. CFO Max Krakowiak has previously indicated that if organic growth exceeds the forecast, the company could see additional margin leverage, a comment that will likely be probed for more detail.

Betting on Innovation and AI

Revvity’s long-term answer to the growth question appears to be a deep and sustained investment in innovation, with a particular emphasis on artificial intelligence. The company's executive team has consistently highlighted its portfolio transformation and the integration of AI as a key differentiator. This strategy is now moving from an internal concept to a core part of its customer-facing value proposition.

Recent strategic moves underscore this focus. In late 2025, Revvity launched Signals Xynthetica, an AI-augmented design platform for molecular discovery, and announced its intent to acquire ACD/Labs to bolster its research informatics software suite. These moves are designed to create what Krakowiak has termed an AI “lab-in-the-loop,” integrating computational design with real-world experimental data to speed up preclinical drug development.

A landmark collaboration with pharmaceutical giant Lilly, announced in January 2026, further validates this approach. The partnership will expand biotech access to Lilly’s predictive AI drug discovery models through Revvity’s Signals software platform. This not only provides a new revenue stream but also positions Revvity at the center of an ecosystem aimed at making AI-driven discovery more accessible. Internally, the company has deployed a custom AI environment for all 11,000 employees to drive productivity, demonstrating a commitment to leveraging the technology at every level.

Navigating a Shifting Health Science Landscape

Revvity's strategic bets are well-aligned with powerful trends shaping the broader health science industry. The global multi-omics market, a core focus for the company, is projected to surpass $5 billion in 2026 and is growing at a compound annual rate of over 15%. This growth is driven by the demand for personalized medicine, advancements in sequencing technology, and the increasing need to understand the complex biological drivers of chronic diseases.

Revvity is positioning its technologies to serve this expanding market, from discovery to diagnosis. Product launches like its pHSense™ reagents for drug discovery and its collaboration on somatic cancer reference standards aim to improve the accuracy and throughput of research and diagnostics. The company’s significant contract to help screen UK newborns for rare diseases is a tangible example of its “diagnosis to cure” mission, demonstrating a direct impact on public health outcomes.

As Revvity’s leadership prepares to take the stage, they will be armed with a narrative of strategic transformation and technological leadership in high-growth fields. The challenge will be to convince a data-driven investment community that this long-term vision can overcome near-term market softness and translate into the robust, profitable growth that shareholders are looking for. The upcoming fireside chats will therefore be a crucial test of management's ability to articulate a clear and convincing path forward, turning technological promise into tangible financial momentum.